• 内刊赠阅
  • |
  • |
  • 行业内参
  • |
  • 帮助中心
  • |
  • 关于我们
  • |
注 册
中国+86
  • +123
  • +125
  • +666
  • +666
  • +555555
  • +666
  • +666
  • +666
请输入真实手机号
请输入图片验证码
请输入短信验证码
请输入密码

已有账号,

忘记密码
中国+86
  • +123
  • +125
  • +666
  • +666
  • +555555
  • +666
  • +666
  • +666
请输入真实手机号
请输入图片验证码
请输入短信验证码
请输入新密码

已有账号,

关于“同仁堂”的报告

本报告研究涉及企业/品牌/案例:同仁堂、香雪制药、白云山。

数据显示,2020年第三季度,中药材价格指数迎来上涨周期。艾媒咨询分析师认为,受动物类等少数品种拉动影响,预计2020年10-11月中药材指数会持续走高,但是在12月维稳。据调查,绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营,采取减少压货炒作等经营方式。因而,预计中药材市场在2020年末旺季会有一波行情的走高,但随着旺季结束,明年年初的价格会重新回落,随着疫情的常态化,中药材市场行情预期会呈周期性波动的态势。

Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation.

本报告研究涉及企业/品牌/案例:无限极,汤臣倍健,康宝莱,Swisse;其他提及企业/品牌:安利,东阿阿胶,合生元,完美,同仁堂,新时代健康,惠氏

iiMedia Research (艾媒咨询)数据显示,过去6年保健品行业市场规模保持两位数的增速,至2019年,市场规模约达2227亿元,2021年有望突破3300亿元。随着健康消费观念提升,养生需求从“银发一族”逐渐往“年轻一代”扩散。此外新兴科技与行业融合将推动产品和服务升级,为行业发展带来利好。消费者方面,超四成的受访者将产品品牌作为其购买时首要考虑因素,其中43.8%的消费者是自发购买保健品的,另外消费者对保健品行业的信心逐渐恢复,五成受访者看好保健品行业发展,超七成受访消费者认为保健品行业合规性有所提高。艾媒咨询分析师认为,目前保健品行业呈较好发展态势,但与此同时保健品行业同质化竞争激烈,在消费人群的扩大化、细分化的趋势下,企业需要通过加强品牌建设和精细化管理,提升产品及服务品质,更好适应市场变化。

According to the data of iiMedia Research,in the past 6 years, the market size of the health products industry has maintained a double-digit growth rate. By 2019, the market size will be approximately 222.7 billion yuan, which is expected to exceed 330 billion yuan in 2021. With the upgrading concept of healthy consumption, the demand for health care has gradually spread from the “silver-haired people” to the “younger generation”. In addition, the integration of emerging technologies and industries will promote the improving of products and services, bringing benefits to the development of the industry. In terms of consumers, over 40% of the interviewees regard product brand as their primary consideration when purchasing. 43.8% of consumers purchase health products spontaneously. In addition, consumer confidence in the health care product industry has gradually recovered. Nearly 50% of the respondents are optimistic about the development of the health care product industry, and over 70% of the consumers believe that the compliance of the health care product industry has improved. Besides, consumer confidence in the health care product industry has gradually recovered. Nearly 50% of the respondents are optimistic about the development of the health care product industry, and over 70% of the interviewed consumers believe that the compliance of the health care product industry has improved. iiMedia Consulting analysts believe that the current health care industry is showing a good development trend, but at the same time, under the trend of expanding and subdividing consumer groups ,the homogenization of the health care industry is fiercely competitive. Enterprises need to enhance the quality of products and services by strengthening brand building and refined management to better adapt to market changes.

本报告研究涉及企业/品牌/案例:同仁堂,片仔癀,东阿阿胶,太极集团,胡庆余堂,同仁牛黄清心丸,黄芪颗粒,雷氏丹参片,云峰气血口服液,太极五子衍宗丸,太极生力雄丸,仲景左归丸,一笑堂龟甲壳,白云山复方丹参片,天士力养血清脑颗粒,白云山夏桑菊颗粒,白云山板蓝根颗粒

随着居民消费水平的提升和健康保健意识的增强,总体健康需求在扩大,进而推动中医药市场的发展,2018年中国中药材市场规模达1246亿元,同比增长22.40%,预计到2024年,中药材市场规模将达2004亿元。
iiMedia Research(艾媒咨询)调查显示,2019年接近五成受访者购买过中药材,滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛,中医药产业链不断扩展延伸,并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场,建设中药大健康产业,如植物提取物、保健食品、中药化妆品等,已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.

(以下为节选页,完整版共88页)

本报告研究涉及企业/品牌/案例:白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业,培力控股,盛实百草,芍花堂,亳药千草,汇群中药

国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research(艾媒咨询)调查显示,有49%的受访用户倾向中医药治疗,与西药基本持平。2018年中国中药材市场规模达1246亿元,同比增长22.40%,在巨大的需求驱动下,中药材种植面积扩大,药材产量将会持续增长。

中药材主要包括上游种植、养殖市场,中游流通市场和下游销售市场三大环节。目前,中药饮片和中成药生产是中药产业的核心,主要包括中药加工,包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面,行业销售收入增速分别在2016和2018年触底回升,华润三九、中国中药、红日药业等上市公司表现良好;中药配方颗粒方面,2006-2016年,中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%,中药配方颗粒或将成为中药饮片加工行业应用广泛的产品;中成药方面,随着国家医改政策的推行,中成药消费需求趋于合理,中成药产量开始回落,但仍处于一个比较高的产量水平,云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。

Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.

没找到想要的报告?

没有你想要的报告?立即告诉我们!

提交报告反馈

在线
客服